In 2019, research revealed that verteporfin, by blocking YAP1 (a transcriptional regulator of genes that promote cell survival and proliferation) and STAT3, might become an appropriate medicine for targeted therapy of cancer stem cells (CSCs), which may be the promise of targeted therapy for BC (31). This evidence concerns the gene STAT3 and breast cancer.